Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 8, 2003 - Issue 1
Submit an article Journal homepage
29
Views
0
CrossRef citations to date
0
Altmetric
Review

Emerging treatments forallergic rhinitis

Morgan Andersson Department of Otorhinolaryngology, University Hospital, SE-221 85 Lund, Sweden
Pages 63-69 | Published online: 02 Mar 2005

Bibliography

  • LINNEBERG A, JORGENSEN T, NIELSEN NH, MADSENF,n FROLUND L, DIRKSEN A: The prevalence of skin-test-positive allergic rhinitis in Danish adults: two cross sectional surveys 8 years apart. The Copenhagen Allergy Study. Allergy (1999) 55:767–772.
  • ANDERSSON M, GREIFF L, SVENSSON C, PERSSON CGA: Allergic and non-allergic rhinitis. In: Asthma and rhinitis (2nd ed). Busse WW, Holgate ST (Eds), Blackwell Science, Oxford, UK (2000):232–244.
  • HUOVINEN E, KAPRIO J, LAITINEN LA, KOSKENVUO M: Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Chest (1999) 115: 928–936.
  • MALONE DC, LAWSON KA, SMITH DH, ARRIGHI HM, BATTISTA C: A cost of illness study of allergic rhinitis in the United States. J. Allergy Clin. Immune]. (1997) 99:22–27.
  • OKUDA M: Cost implication of allergic rhinitis. Allergy Immune]. (1998) 5:86–91.
  • GENGO FM, MANNING C: A review of the effects of antihistamines on mental processes related to automobile driving. I Allergy Clin. Immune]. (1990) 86:1034–1039.
  • BOUSQUET J, VAN CAUWENBERGE P,KHALTAEV N: Allergic rhinitis and its impact on asthma. ARIA workshop report. I Allergy Clin. Immunol. (2001) 108\(Suppl. 5):S147-S334. The present position for treatment of allergic rhinitis, with a large list of references.
  • YANEZ A, RODRIGO GJ: Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann. Allergy Asthma Immunol (2002) 89:479–484.
  • DAVIES RJ, BAGNALL AC, MCCABE RN, CALDERON MA, WANG JH: Antihistamines: topical versus oral administration. Clin. Exp. Allergy (1996) 26\(Suppl. 3):11–17.
  • OSUNA AL, CABALLERO GR, CORTES MMT, ALDANA OI: Levocabastine versus cetirizine for perennial allergic rhinitis in children. Rev. Aleig. Mex. (1998) 45:7–11.
  • MCNEELY W, WISEMAN LR: Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs (1998) 56:91–114.
  • WEINER JM, ABRAMSON MJ, PUY RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br. Med. (1998) 317:1624–1629.
  • •Important meta-analysis of several double-blind, placebo controlled studies, comparing antihistamines and intranasal steroids. Intranasal steroids are more effective than antihistamines.
  • CERVIN A, ANDERSSON M: Intranasal steroids and septal perforation- an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology (1998) 36:128–132.
  • PEARLMAN DS: Pathophysiology of the inflammatory response. J. Allergy an. Immunol. (1999) 104:132–137.
  • •A well written introduction to the pathophysiology of rhinitis.
  • MYGIND N: Nasal inflammation and anti-inflammatory treatment. Semantics or clinical reality. Rhinology (2001) 39: 61–65.
  • BARNES PJ: Pathophysiology of allergic inflammation. In: Allergy: Principles and practice (5th ed)Middletone E JR, Reed CE, Ellis EF, Adkinson NF JR, Yunginer JW, Busse WW (Eds), Mosby, St Louis, USA (1998):356–365.
  • DI RIENZO V, PUCCINELLI P, FRATI F,PARMIANI S: Grass pollen specific/ swallow immunotherapy in children. Open controlled comparison among different treatment protocols. Allergol. Immunopathol. (Madi) (1999) 27:145–151.
  • WHO POSITION PAPER: Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27–29 1997.Bousquet J, Lockey RF, Mailing H-J (Eds), Allergy (1998) 53\(Suppl. 44):1–42.
  • WIEDERMANN U, HERZ U, BAIER K et al.: Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen Bet v 1 prevents allergenic sensitisation and airway inflammation in mice. Lit. Arch. Allergy Immunol. (2001) 106:101–109.
  • NORMAN PS, OHMAN JL JR, LONG AA et al.: Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. (1996) 154:1623–1628.
  • ADELROTH E, RAK S, HAATHELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. Allergy Clin. Immunol. (2000) 106:253–259.
  • LEYNADIER F, MEES K, ARENDT C, PINELLI ME: Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol. Belg. (2001) 55:305–312.
  • NAYAK AS, PHILIP G, LU S, MALICE MP, REISS TF: Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol. (2002) 88:592–600.
  • PHILIP G, MALMSTROM K, HAMPEL FC et al.: Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin. Exp. Allergy (2002) 32: 1020–1028.
  • PULLERITS T, PRAKS L, RISTIOJA V, LOT VALL J: Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriens and anthistamines in the treatment of seasonal allergic rhinitis. I Allergy Clin. Immunol. (2002) 109:949–955.
  • •A study comparing leukotriene antagonist, combination therapy and intranasal steroids in seasonal allergic rhinitis. The topical glucocorticosteroid is clearly more effective than antileukotirenes as well as a combination of antileukotrienes and antihistamines.
  • ZETTERSTROM O, BUHL R, MELLEM H et al.: Improved asthma control with budesonide/formoterol in a single inhaler compared with budesonide alone. Ear: Respir. 1 (2001) 18:262–268.
  • LECKIE MJ, TEN BRINKE A, KHAN J et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2144–2148.
  • •Important study where anti-IL-5 therapy reduced the numer of eosinoophils, but the asthma disease was not improved.
  • VAN WAUWE J, AERTS F, COOLS M et al.: Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. J. Pharmacol. Exp. The]: (2000) 295:655–661.
  • BRYAN SA, O'CONNOR BJ, LECKIE MJ et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet (2000) 356:2149–2153.
  • BAUMER W, GORR G, HOPPMANN J, EHINGER AM, EHINGER B, KIETZMANN M: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis. Eur. Pharmacol. (2002) 446:195–200.
  • GORE RB, HADI EA, CRAVEN M et al.:Personal exposure to house dust mite allergen in bed: nasal air sampling and reservoir allergen levels. an. Exp. Allergy (2002) 32:856–859.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.